Literature DB >> 27911449

Allogeneic blood-based therapies: hype or hope?

E Anitua1,2, M de la Fuente2, J Merayo-Lloves3, F Muruzabal2, G Orive1,2,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27911449      PMCID： PMC5395995          DOI： 10.1038/eye.2016.268

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  5 in total

1.  Allogeneic serum eye drops for the treatment of persistent corneal epithelial defect.

Authors:  C-C Chiang; W-L Chen; J-M Lin; Y-Y Tsai
Journal:  Eye (Lond)       Date:  2008-01-11       Impact factor: 3.775

Review 2.  Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies.

Authors:  Eduardo Anitua; Francisco Muruzabal; Ali Tayebba; Ana Riestra; Victor L Perez; Jesus Merayo-Lloves; Gorka Orive
Journal:  Acta Ophthalmol       Date:  2015-04-02       Impact factor: 3.761

Review 3.  Component pathogen inactivation: a critical review.

Authors:  C V Prowse
Journal:  Vox Sang       Date:  2012-11-08       Impact factor: 2.144

4.  Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease.

Authors:  Kyung-Sun Na; Man Soo Kim
Journal:  J Ocul Pharmacol Ther       Date:  2012-06-25       Impact factor: 2.671

5.  Effects of heat-treatment on plasma rich in growth factors-derived autologous eye drop.

Authors:  E Anitua; F Muruzabal; M De la Fuente; J Merayo-Lloves; G Orive
Journal:  Exp Eye Res       Date:  2013-12-15       Impact factor: 3.467
  5 in total
  1 in total

Review 1.  Blood-Based Treatments for Severe Dry Eye Disease: The Need of a Consensus.

Authors:  Federico Bernabei; Matilde Roda; Marina Buzzi; Marco Pellegrini; Giuseppe Giannaccare; Piera Versura
Journal:  J Clin Med       Date:  2019-09-17       Impact factor: 4.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.